<PAGE>
As filed with the Securities and Exchange Commission on March 16, 2000.
Registration No. 333-92603
- -------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Amendment No. 2
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
THE IMMUNE RESPONSE CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 33-0255679
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
5935 Darwin Court
Carlsbad, California 92008
(760) 431-7080
(Address, including zip code, and telephone number, including
area code of registrant's principal executive offices)
DENNIS J. CARLO, Ph.D. Copies to:
President and Chief Executive Officer THOMAS E. SPARKS, JR., ESQ
The Immune Response Corporation ALAN G. SMITH, ESQ.
5935 Darwin Court Pillsbury Madison & Sutro LLP
Carlsbad, California 92008 P. O. Box 7880
(760) 431-7080 San Francisco, CA 94120-7880
(Name, address, including zip code, and telephone (415) 983-1000
number, including area code, of agent for service)
Approximate date of commencement of proposed sale to the public: From time to
time after the effective date of this Registration Statement as determined by
the Selling Stockholder.
If the only securities being registered on this Form are being offered pursuant
to dividend or interest reinvestment plans, please check the following box: [ ]
If any of the securities being registered on this Form are to be offered on a
delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, other than securities offered only in connection with dividend or interest
reinvestment plans, please check the following box: [x]
If this Form is filed to register additional securities for an offering pursuant
to Rule 462(b) under the Securities Act, please check the following box and list
the Securities Act registration statement number of the earlier effective
registration statement for the same offering: [ ]
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under
the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering: [ ]
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box: [ ]
---------------
CALCULATION OF REGISTRATION FEE
<TABLE>
<CAPTION>
- --------------------------------------------------------------------------------------------------------------------------
- --------------------------------------------------------------------------------------------------------------------------
PROPOSED MAXIMUM PROPOSED MAXIMUM AMOUNT OF
TITLE OF EACH CLASS OF SECURITIES TO AMOUNT TO BE OFFERING PRICE PER AGGREGATE OFFERING REGISTRATION
BE REGISTERED REGISTERED(1)(3)(4) SHARE(2) PRICE FEE(3)
- --------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Common Stock, $.0025 par value 2,307,000 shares $3.703 $8,542,821 $2,255.30
- --------------------------------------------------------------------------------------------------------------------------
- --------------------------------------------------------------------------------------------------------------------------
</TABLE>
(1) Represents shares issuable upon conversion of, or upon issuance of
dividends on, the Company's Series F Convertible Preferred Stock.
(2) Estimated solely for the purpose of calculating the registration fee
pursuant to Rule 457(c), based upon the average of the high and low
price reported on the Nasdaq National Market on December 6, 1999.
(3) Previously paid. In addition, pursuant to Rule 429, the combined
prospectus relates to that filed with Registration Statement
No. 333-56441. 1,593,000 Shares of the Company's Common Stock from
that Registration Statement are included in the prospectus. A filing
fee of $5,345.92 was previously paid with respect to those shares.
(4) Of the 3,900,000 shares of the Company's Common Stock registered
under this Registration Statement, 2,430,471 Shares are currently
offered, of the remaining 1,469,529 shares, approximately 222,337
shares are registered to cover dividends that may be payable to the
selling stockholder in Common Stock and the remaining shares are
registered pursuant to the terms of the Securities Purchase
Agreement, dated as of April 24, 1998 by and among us and the
selling stockholder to cover possible downward adjustments to the
conversion price.
The registrant hereby amends this Registration Statement on such date or dates
as may be necessary to delay its effective date until the registrant shall file
a further amendment which specifically states that this Registration Statement
shall thereafter become effective in accordance with Section 8(a) of the
Securities Act of 1933 or until the Registration Statement shall become
effective on such date as the Commission, acting pursuant to said Section 8(a),
may determine.
<PAGE>
The information in this prospectus is not complete and may be changed.
The selling stockholder may not sell these securities under this prospectus
until the registration statement filed with the Securities and Exchange
Commission is effective. This prospectus is not an offer to sell these
securities and is not soliciting an offer to buy these securities in any state
where the offer or sale is not permitted.
Subject to Completion, Dated March 16, 2000
THE IMMUNE RESPONSE CORPORATION
2,430,471 SHARES OF COMMON STOCK
--------------
This prospectus is part of a registration statement we filed with the
Securities and Exchange Commission, which will be used by HFTP Investment
L.L.C to resell the common stock issuable upon conversion of, or upon
issuance of dividends on, 200 shares of Series F Convertible Preferred Stock.
Our common stock is listed on the Nasdaq National Market under the
symbol "IMNR." On March 15, 2000, the last reported sale price for our common
stock on the Nasdaq National Market was $11.875 per share.
--------------
INVESTING IN OUR COMMON STOCK INVOLVES RISKS. SEE "RISK FACTORS"
BEGINNING ON PAGE 2.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED THESE SECURITIES OR PASSED UPON THE
ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL
OFFENSE.
--------------
The date of this Prospectus is ____________, 2000
-1-
<PAGE>
RISK FACTORS
YOU SHOULD CAREFULLY CONSIDER THE RISKS DESCRIBED BELOW BEFORE MAKING AN
INVESTMENT DECISION. THE RISKS AND UNCERTAINTIES DESCRIBED BELOW ARE NOT THE
ONLY ONES FACING US. ADDITIONAL RISKS AND UNCERTAINTIES NOT PRESENTLY KNOWN TO
US OR THAT WE CURRENTLY DEEM IMMATERIAL MAY ALSO IMPAIR OUR BUSINESS.
IF ANY OF THE FOLLOWING RISKS ACTUALLY OCCUR, OUR BUSINESS COULD BE
ADVERSELY AFFECTED. IN THOSE CASES, THE TRADING PRICE OF OUR COMMON STOCK COULD
DECLINE, AND YOU MAY LOSE ALL OR PART OF YOUR INVESTMENT.
THE FAILURE TO SUCCESSFULLY DEVELOP AND COMMERCIALIZE PRODUCTS MAY CAUSE US TO
CEASE OPERATIONS.
We have not completed the development of any products. A failure to
successfully develop and commercialize products may cause us to cease
operations. Our potential therapies under development will require significant
additional research and development efforts and regulatory approvals prior to
potential commercialization.
The conclusion of the Phase III trial of REMUNE due to lack of efficacy
has had a material adverse effect on us. If Agouron Pharmaceuticals, Inc. fails
to initiate or successfully complete additional pivotal trials with REMUNE we
may have to abandon REMUNE or seek additional funding.
Our other therapies and technologies are at earlier stages of
development than REMUNE. Some of our technologies have not yet been tested in
humans. Human testing of potential products based on these technologies may not
be permitted by regulatory authorities. Even if human testing is permitted, the
products based on these technologies may not be successfully developed or be
shown to be safe and efficacious. Potential immune-based therapies based on some
of our technologies are at an early stage of clinical testing and may not be
shown to be safe or efficacious or ever receive regulatory approval.
The results of our preclinical studies and clinical trials may not be
indicative of future clinical trial results. A commitment of substantial
resources to conduct time-consuming research, preclinical studies and clinical
trials will be required if we are to develop any products. Delays in planned
patient enrollment in our clinical trials may result in increased costs, program
delays or both. None of our potential products may prove to be safe and
effective in clinical trials. FDA or other regulatory approvals may not be
obtained and even if successfully developed and approved, our products may not
achieve market acceptance. Any products resulting from our programs are not
expected to be successfully developed or commercially available for a number of
years, if at all.
Unacceptable toxicities or side effects may occur at any time in the
course of human clinical trials or, if any products are successfully developed
and approved for marketing, during commercial use of our products. The
appearance of any unacceptable toxicities or side effects
-2-
<PAGE>
could interrupt, limit, delay or abort the development of any of our products
or, if previously approved, necessitate their withdrawal from the market.
OUR ADDITIONAL FINANCING REQUIREMENTS AND LIMITED ACCESS TO FINANCING MAY
ADVERSELY AFFECT OUR ABILITY TO DEVELOP PRODUCTS
We will need to raise additional funds to conduct research and
development, preclinical studies and clinical trials necessary to bring our
potential products to market and establish manufacturing and marketing
capabilities. A failure to raise additional funds would require us to scale back
or eliminate some or all of our research and development programs or license to
third parties products or technologies that we would otherwise seek to develop
ourselves. We believe that our existing resources, will enable us to maintain
our current and planned operations only into early 2001.
Our anticipated costs with respect to REMUNE will depend on many
factors, in particular the continuation of our collaboration with Agouron
Pharmaceuticals, Inc.
Our future capital requirements will depend on many factors, including:
- continued scientific progress in our research and development
programs,
- the scope and results of preclinical studies and clinical trials,
the time and costs involved in obtaining regulatory approvals,
- the costs involved in filing, prosecuting and enforcing patent
claims,
- competing technological and market developments,
- the cost of manufacturing scale-up,
- effective commercialization activities and arrangements, and
- other factors not within our control.
We intend to seek additional funding through public or private
financings, arrangements with corporate collaborators or other sources. If funds
are acquired through additional collaborations, we will likely be required to
relinquish some or all of the rights to products that we may have otherwise
developed ourselves. If adequate funds are not available when needed or on terms
acceptable to us, we may be required to scale back some or all of our research
and development programs or license to third parties products or technologies
that we would otherwise seek to develop ourselves.
-3-
<PAGE>
IF AGOURON PHARMACEUTICALS, INC. TERMINATES ITS COLLABORATION WITH US WE MAY
HAVE TO ABANDON REMUNE
Our binding Letter of Intent with Agouron Pharmaceuticals, Inc. is the
primary collaborative agreement that provides us with contract revenue. The
termination of our agreement with Agouron might require us to abandon REMUNE.
Agouron has been acquired by Warner Lambert Company. We do not know which
Agouron research projects Warner Lambert Company will continue to fund in the
future.
WE MAY NOT BE ABLE TO ENTER INTO ADDITIONAL COLLABORATIONS
We intend to seek additional collaborative arrangements to develop and
commercialize our products. We may not be able to negotiate collaborative
arrangements on favorable terms, or at all, in the future and our current or
future collaborative arrangements may not be successful. This may cause us to
abandon some of our products under development.
OUR PATENTS AND PROPRIETARY TECHNOLOGY MAY NOT PROVIDE US WITH ANY BENEFIT AND
THE PATENTS AND PROPRIETARY TECHNOLOGY OF OTHERS MAY PREVENT US FROM
COMMERCIALIZING PRODUCTS
A failure to obtain meaningful patent protection for our potential
products and processes would greatly diminish the value of our potential
products and processes.
In addition, whether or not our patents are issued, or issued with
limited coverage, others may receive patents which contain claims applicable
to our products. We are aware that AstraZeneca PLC has acquired the rights to
a patent, which has been issued in Europe and other countries, that may
interfere with our ability to develop some of our technologies related to
autoimmune disease if the patent is upheld after current opposition
proceedings. These patents, and others that we are not aware of, may
adversely affect our ability to develop and commercialize products.
The patent positions of biotechnology and pharmaceutical companies can
be highly uncertain, and involve complex legal and factual questions. Therefore,
the breadth of claims allowed in biotechnology and pharmaceutical patents cannot
be predicted. We also rely upon unpatented trade secrets and know how, and
others may independently develop substantially equivalent trade secrets or know
how.
We also rely on protecting our proprietary technology in part through
confidentiality agreements with our corporate collaborators, employees,
consultants and certain contractors. These agreements may be breached and we may
not have adequate remedies for any breach. In addition, our trade secrets may
otherwise become known or independently discovered by our competitors.
-4-
<PAGE>
Our products and processes may infringe, or be found to infringe,
patents not owned or controlled by us, such as the patent owned by
AstraZeneca PLC. If relevant claims of third-party patents are upheld as
valid and enforceable, we could be prevented from practicing the subject
matter claimed in the patents, or would be required to obtain licenses or to
redesign our products or processes to avoid infringement. Licenses may not be
available at all or on terms commercially reasonable to us and we may not be
able to redesign our products or processes to avoid infringement.
Litigation may be necessary to defend against claims of infringement, to
enforce patents issued to us or to protect trade secrets. Litigation could
result in substantial costs and diversion of management efforts regardless of
the results of the litigation. An adverse result in litigation could subject us
to significant liabilities to third parties, require disputed rights to be
licensed or require us to cease using some technology.
OUR HISTORY OF OPERATING LOSSES AND OUR EXPECTATIONS OF CONTINUING LOSSES MAY
HURT OUR ABILITY TO CONTINUE OPERATIONS
As of September 30, 1999, we had a consolidated accumulated deficit of
$184.429 million. We have not generated revenues from the commercialization of
any product. We expect to incur substantial net operating losses over the next
several years which may imperil our ability to continue operations. We may not
be able to generate sufficient product revenue to become profitable at all or on
a sustained basis.
THE LENGTHY APPROVAL PROCESS AND UNCERTAINTY OF GOVERNMENT REGULATORY
REQUIREMENTS MAY DELAY OR PREVENT US FROM COMMERCIALIZING PRODUCTS
Clinical testing, manufacture, promotion and sale of our products are
subject to extensive regulation by numerous governmental authorities in the
United States, principally the FDA, and corresponding state and foreign
regulatory agencies. This regulation may delay or prevent us from
commercializing products. Noncompliance with applicable requirements can result
in, among other things, fines, injunctions, seizure of products, total or
partial suspension of product marketing, failure of the government to grant
premarket approval, withdrawal of marketing approvals and criminal prosecution.
The regulatory process for new therapeutic drug products, including the
required preclinical studies and clinical testing, is lengthy and expensive. We
may not receive necessary FDA clearances for any of our potential products in a
timely manner, or at all. The length of the clinical trial process and the
number of patients the FDA will require to be enrolled in the clinical trials in
order to establish the safety and efficacy of our products is uncertain.
Even if additional pivotal surrogate marker trials of REMUNE are
successfully completed, the FDA may not approve REMUNE for commercial sale. We
may encounter significant delays or excessive costs in our efforts to secure
necessary approvals. Regulatory requirements are evolving and uncertain. Future
United States or foreign legislative or administrative acts could also prevent
or delay regulatory approval of our products. We may not be able to obtain the
necessary approvals for clinical trials, manufacturing or marketing of any of
our products under
-5-
<PAGE>
development. Even if commercial regulatory approvals are obtained, they may
include significant limitations on the indicated uses for which a product may be
marketed.
In addition, a marketed product is subject to continual FDA review.
Later discovery of previously unknown problems or failure to comply with the
applicable regulatory requirements may result in restrictions on the marketing
of a product or withdrawal of the product from the market, as well as possible
civil or criminal sanctions.
Among the other requirements for regulatory approval is the requirement
that prospective manufacturers conform to the FDA's Good Manufacturing Practices
("GMP") requirements specifically for biological drugs, as well as for other
drugs. In complying with the FDA's GMP requirements, manufacturers must continue
to expend time, money and effort in production, recordkeeping and quality
control to assure that the product meets applicable specifications and other
requirements. Failure to comply with the FDA's GMP requirements subjects the
manufacturer to possible FDA regulatory action. We or our contract
manufacturers, if any, may not be able to maintain compliance with the FDA's GMP
requirements on a continuing basis. Failure to maintain compliance could have a
material adverse effect on us.
The FDA has not designated expanded access protocols for REMUNE as
"treatment" protocols. The FDA may not determine that REMUNE meets all of the
FDA's criteria for use of an investigational drug for treatment use. Even if
REMUNE is allowed for treatment use, third party payers may not provide
reimbursement for the costs of treatment with REMUNE.
The FDA may not consider REMUNE or any other of the Company's products
under development to be an appropriate candidate for accelerated approval,
expedited review or fast track designation.
To market any drug products outside of the United States, we are also
subject to numerous and varying foreign regulatory requirements, implemented by
foreign health authorities, governing the design and conduct of human clinical
trials and marketing approval. The approval procedure varies among countries and
can involve additional testing, and the time required to obtain approval may
differ from that required to obtain FDA approval. The foreign regulatory
approval process includes all of the risks associated with obtaining FDA
approval set forth above, and approval by the FDA does not ensure approval by
the health authorities of any other country.
TECHNOLOGICAL CHANGE AND COMPETITION MAY RENDER OUR POTENTIAL PRODUCTS OBSOLETE
The biotechnology industry continues to undergo rapid change and
competition is intense and is expected to increase. Competitors may succeed in
developing technologies and products that are more effective or affordable than
any which are being developed by us or which would render our technology and
products obsolete and noncompetitive. Many of our competitors have substantially
greater experience, financial and technical resources and production, marketing
and development capabilities than us. Accordingly, some of our competitors may
succeed in obtaining regulatory approval for products more rapidly or
effectively than us.
-6-
<PAGE>
OUR LACK OF COMMERCIAL MANUFACTURING AND MARKETING EXPERIENCE MAY PREVENT US
FROM SUCCESSFULLY COMMERCIALIZING PRODUCTS
We have not manufactured our product candidates in commercial
quantities. We may not successfully make the transition from manufacturing
clinical trial quantities to commercial production quantities or be able to
arrange for contract manufacturing and this could prevent us from
commercializing products. Even if REMUNE is successfully developed and receives
FDA approval, we have not demonstrated the capability to manufacture REMUNE in
commercial quantities. Except for REMUNE, we have not demonstrated the ability
to manufacture our treatments in large-scale clinical or commercial quantities.
We have no experience in the sales, marketing and distribution of
pharmaceutical products. Thus, our products may not be successfully
commercialized even if they are developed and approved for commercialization.
The manufacturing of our products involves a number of steps and
requires compliance with stringent quality control specifications imposed by us
and by the FDA. Moreover, our products can only be manufactured in a facility
that has undergone a satisfactory inspection by the FDA. For these reasons, we
would not be able quickly to replace our manufacturing capacity if we were
unable to use our manufacturing facilities as a result of a fire, natural
disaster (including an earthquake), equipment failure or other difficulty, or if
such facilities are deemed not in compliance with the FDA's GMP requirements and
the non-compliance could not be rapidly rectified. Our inability or reduced
capacity to manufacture our products would prevent us from successfully
commercializing products.
We may enter into arrangements with contract manufacturing companies to
expand our own production capacity in order to meet requirements for our
products, or to attempt to improve manufacturing efficiency. If we choose to
contract for manufacturing services and encounters delays or difficulties in
establishing relationships with manufacturers to produce, package and distribute
our finished products, clinical trials, market introduction and subsequent sales
of the products would be delayed. Further, contract manufacturers must also
operate in compliance with the FDA's GMP requirements; failure to do so could
result in, among other things, the disruption of product supplies. Our potential
dependence upon third parties for the manufacture of our products may adversely
affect our profit margins and our ability to develop and deliver products on a
timely and competitive basis.
ADVERSE DETERMINATIONS CONCERNING PRODUCT PRICING, REIMBURSEMENT AND RELATED
MATTERS COULD PREVENT US FROM SUCCESSFULLY COMMERCIALIZING PRODUCTS
Our ability to earn sufficient returns on our products will depend in
part on the extent to which reimbursement for the costs of the products and
related treatments will be available from government health administration
authorities, private health coverage insurers, managed care organizations and
other organizations. Failure to obtain appropriate reimbursement could prevent
us from successfully commercializing products. Third party payors are
increasingly challenging the price of medical products and services. If
purchasers or users of our products are not able to obtain adequate
reimbursement for the cost of using the products, they may forego or reduce
-7-
<PAGE>
their use. Significant uncertainty exists as to the reimbursement status of
newly approved health care products, and whether adequate third party coverage
will be available.
PRODUCT LIABILITY EXPOSURE MAY EXPOSE US TO SIGNIFICANT LIABILITY
We face an inherent business risk of exposure to product liability and
other claims in the event that the development or use of our technology or
prospective products is alleged to have resulted in adverse effects. We may not
avoid significant liability exposure. We may not have sufficient insurance
coverage and we may not be able to obtain sufficient coverage, at a reasonable
cost. An inability to obtain product liability insurance at acceptable cost or
to otherwise protect against potential product liability claims could prevent or
inhibit the commercialization of products developed by us. A product liability
claim could hurt our financial performance.
HAZARDOUS MATERIALS/ENVIRONMENTAL MATTERS COULD EXPOSE US TO SIGNIFICANT COSTS
Although we do not currently manufacture commercial quantities of our
product candidates, we produce limited quantities of these products for our
clinical trials. We may be required to incur significant costs to comply with
current or future environmental laws and regulations. Our research and
development processes involve the controlled storage, use and disposal of
hazardous materials, biological hazardous materials and radioactive compounds.
We are subject to federal, state and local laws and regulations governing the
use, manufacture, storage, handling and disposal of these materials and some
waste products. Although we believe that our safety procedures for handling and
disposing of these materials comply with the standards prescribed by these laws
and regulations, the risk of accidental contamination or injury from these
materials cannot be completely eliminated. In the event of an accident, we could
be held liable for any damages that result, and any liability could exceed our
resources. Our operations, business or assets may be materially and adversely
affected by current or future environmental laws or regulations.
SUBORDINATION OF COMMON STOCK TO PREFERRED STOCK COULD HURT COMMON STOCKHOLDERS
Our common stock is expressly subordinate to our Series F Convertible
Preferred Stock in the event of our liquidation, dissolution or winding up. If
we were to cease operations and liquidate our assets, there may not be any
remaining value available for distribution to the holders of common stock after
providing for the Series F Convertible Preferred Stock liquidation preference.
DILUTION CAUSED BY CONVERSION OF PREFERRED STOCK COULD HURT COMMON STOCKHOLDERS.
As of December 1, 1999, the Series F Convertible Preferred Stock was
convertible into Common Stock at a price of $4.166 per share of common stock.
As of December 1, 1999, the 2,430,471 shares of common stock into which
the Series F Convertible Preferred Stock could convert constituted
approximately 9.4% of outstanding common stock, without regard to any
limitations on conversions.
The conversion of the Series F Convertible Preferred Stock into
common stock and the sale of the common stock may cause our stock price to
fall. This conversion price may be adjusted downward. This would result in
more shares of common stock being issued against conversion of the Series F
Convertible Preferred Stock which could cause ever greater dilution to our
stockholders.
VOLATILITY OF STOCK PRICE AND ABSENCE OF DIVIDENDS MAY HURT COMMON STOCKHOLDERS
The market price of our common stock, like that of the common stock of
many other biopharmaceutical companies, has been and is likely to be highly
volatile. Factors such as:
- the results of preclinical studies and clinical trials by us,
our collaborators or our competitors,
-8-
<PAGE>
- other evidence of the safety or efficacy of our products or
our competitors,
- announcements of technological innovations or new products by
us or our competitors,
- governmental regulatory actions,
- changes or announcements in reimbursement policies,
- developments with our collaborators,
- developments concerning patent or other proprietary rights of
ours or our competitors (including litigation),
- concern as to the safety of our products,
- period-to-period fluctuations in our operating results,
- changes in estimates of our performance by securities
analysts,
- market conditions for biopharmaceutical stocks in general, and
- other factors not within our control
could have a significant adverse impact on the market price of our common stock.
We have never paid cash dividends on our common stock and do not anticipate
paying any cash dividends in the foreseeable future.
EFFECT OF ANTI-TAKEOVER PROVISIONS COULD ADVERSELY AFFECT OUR COMMON
STOCKHOLDERS
Our Certificate of Incorporation and Bylaws include provisions that
could discourage potential takeover attempts and make attempts by stockholders
to change management more difficult. The approval of 66-2/3 percent of our
voting stock is required to approve certain transactions and to take certain
stockholder actions, including the calling of special meetings of stockholders
and the amendment of any of the anti-takeover provisions contained in our
Certificate of Incorporation. Further, pursuant to the terms of our stockholder
rights plan, we have distributed a dividend of one right for each outstanding
share of common stock. These rights will cause substantial dilution to the
ownership of a person or group that attempts to acquire us on terms not approved
by the Board of Directors and may have the effect of deterring hostile takeover
attempts.
-9-
<PAGE>
ADDITIONAL OR UPDATED RISK FACTORS
Prior to making an investment decision with respect to the common stock
offered hereby, prospective investors should also carefully consider any
specific factors set forth under a caption "risk factors" in the applicable
prospectus supplement, if any, together with all of the other information
appearing in this prospectus or the prospectus supplement or incorporated by
reference into this prospectus.
SPECIAL NOTE REGARDING FORWARD-LOOKING INFORMATION
When used in this prospectus, the words "intends to," "believes,"
"anticipates," "expects" and similar expressions are intended to identify
forward-looking statements. These forward-looking statements are based largely
on our expectations and are subject to a number of risks and uncertainties, some
of which are beyond our control. For a discussion of some of these risks, see
"Risk Factors." These forward-looking statements speak only as of the date of
this prospectus. We expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statement contained
within this prospectus to reflect any change in our expectations with regard to
those forward-looking statements or any change in events, conditions or
circumstances on which any such statement is based.
WHERE YOU CAN FIND MORE INFORMATION
We file annual, quarterly and special reports, proxy statements and
other information with the SEC. This information can be (1) read and copied at
the public reference facilities maintained by the SEC at 450 Fifth Street, N.W.,
Judiciary Plaza, Washington, D.C., and at the SEC's Chicago Regional Office, 500
West Madison Street, Chicago, Illinois; and New York Regional Office, 7 World
Trade Center, New York, New York and (2) accessed via a Web site maintained by
the SEC (http://www.sec.gov). Copies of the material can also be obtained from
the Public Reference Section of the SEC at 450 Fifth Street, N.W., Judiciary
Plaza, Washington, D.C. 20549 at prescribed rates. Please call the SEC at
1-800-SEC-0330 for further information on the public reference rooms.
This prospectus is a part of a registration statement we filed with the
SEC. This prospectus does not contain all of the information set forth in the
registration statement. For more information about us and our common stock, you
should read the registration statement and its exhibits and schedules. Copies of
the registration statement, including its exhibits may be obtained from the
SEC's principal office in Washington, D.C. upon payment of the fees prescribed
by the SEC, or may be examined without charge at the offices of the SEC.
The SEC allows us to "incorporate by reference" the information we file
with them, which means that we can disclose important information to you by
referring you to those documents. The information incorporated by reference is
considered to be part of this prospectus, and later information that we file
with the SEC will automatically update and supersede this information. We
incorporate by reference the documents listed below and any future filings made
by us with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities
Exchange Act of 1934 (File No. 0-18006):
-10-
<PAGE>
(a) Our Annual Report on Form 10-K for the year ended December 31,
1998;
(b) Our Quarterly Report on Form 10-Q for the quarters ended March 31,
1999, June 30, 1999 and September 30, 1999;
(c) Our Current Report on Form 8-K dated May 17, 1999;
(d) Our Current Report on Form 8-K dated May 14, 1999;
(e) The description of our common stock set forth in the registration
statement on Form 8-A filed on March 30, 1990; and
(f) The description of the Preferred Stock Purchase rights for Series E
Participating Preferred Stock, par value $0.001, set forth in the registration
statement on Form 8-A filed on March 4, 1992.
Upon written or oral request, we will provide without charge to each
person to whom a copy of this prospectus is delivered a copy of the documents
incorporated by reference into this prospectus (other than exhibits to these
documents unless the exhibits are specifically incorporated by reference into
those documents). Requests should be submitted in writing or by telephone at
(760) 431-7080 to The Immune Response Corporation, at our principal executive
offices, 5935 Darwin Court, Carlsbad, California 92008.
USE OF PROCEEDS
We will not receive any proceeds from the sale of common stock by the
selling stockholder in the offering.
ISSUANCE OF COMMON STOCK TO THE SELLING STOCKHOLDER
Of the 3,900,000 shares being offered pursuant to this prospectus,
2,430,471 shares of common stock would be issuable upon conversion of
200 shares of our Series F Convertible Preferred Stock as of December 1, 1999.
We entered into an agreement with the selling stockholder which provides that
we must register 150% of the common stock into which the Series F
Convertible Preferred Stock is then convertible. The 2,430,471 shares issuable
as of December 1, 1999 excludes additional shares of common stock which would
be issuable to the selling stockholder upon conversion of the Series F
Convertible Preferred Stock if the conversion price is adjusted further
downward pursuant to the terms of the Series F Convertible Preferred Stock.
The 2,430,471 shares issuable as of December 1, 1999 also excludes shares of
common stock which will be issuable to the selling stockholder to pay the
dividend of 7.5% per annum accruing after December 1, 1999 which is payable
on the Series F Convertible Preferred Stock.
As of the date of this prospectus, the Series F Convertible
Preferred Stock is convertible into our common stock at a conversion price
equivalent to $4.166 per share of our common stock. The conversion price was
adjusted on November 30, 1999 and may readjust every three months thereafter.
The adjusted conversion price will be equal to the average of the
closing bid prices of our common stock during the 30 consecutive trading days
immediately preceding the date of adjustment of the conversion price unless the
conversion price then in effect is lower, in which case the conversion price
will not be adjusted. The conversion price of the Series F Preferred Stock will
also be adjusted for events such as subdivisions or combinations of our common
stock and reorganizations, reclassifications, consolidations, merger or sale of
The Immune Response Corporation.
-11-
<PAGE>
Pursuant to the Securities Purchase Agreement, dated as of April 24,
1998, by and among us and the selling stockholder, we are required to at all
times have authorized, and reserved for the purpose of issuance, no less than
150% of the number of shares of common stock issuable upon conversion of the
Series F Convertible Preferred Stock.
INCOME TAX CONSIDERATIONS
You should consult your own tax advisor about the income tax issues and
the consequences of holding and disposing of our common stock.
-12-
<PAGE>
SELLING STOCKHOLDER
As of December 1, 1999 there was one selling stockholder, as set forth
below. Share ownership information is based solely upon information furnished to
us by HFTP Investment L.L.C.:
<TABLE>
<CAPTION>
Number of Shares of
Common Stock to be
Shares of Common Held After Sale
Stock Issuable Upon Assuming Full
Conversion of the Conversion of
Series F Convertible Series F Convertible
Preferred Stock Number of Preferred Stock and
Held at Shares Being Sale of
Selling Stockholder December 1, 1999(1)(2) Offered(1) Common Stock
- ------------------------------------------ ---------------------- ------------- --------------
<S> <C> <C> <C>
HFTP Investment L.L.C.(3)................ 2,430,471 2,430,471 0
</TABLE>
- ----------
(1) Excludes additional shares of common stock which would be issuable to
the selling stockholder upon conversion of the Series F Convertible
Preferred Stock if the conversion price is adjusted further downward
pursuant to the terms of the Series F Convertible Preferred Stock and
excludes shares of common stock which will be issuable to the selling
stockholder to pay the dividend of 7.5% per annum accruing after
December 1, 1999 which is payable on the Series F Convertible Preferred
Stock. The number of shares of common stock listed as beneficially
owned by HFTP Investment L.L.C. assumes conversion of all shares of
Series F Convertible Preferred Stock held by HFTP Investment L.L.C. on
December 1, 1999 at a conversion price of $4.166, which was the
conversion price in effect on December 1, 1999, without regard to any
limitations on conversion. However, no holder of Series F Convertible
Preferred Stock may convert shares of Series F Convertible Preferred
Stock in excess of the number of shares, which, upon giving effect to
such conversion, would result in the holder, together with its
affiliates, beneficially owning more than 4.99% of the shares of common
stock then outstanding (excluding for purposes of such determination
shares of common stock issuable upon conversion of shares of Series F
Convertible Preferred Stock which have not been converted). We have
registered 3,900,000 shares of common stock for resale by HFTP
Investment L.L.C. As HFTP resells shares or receives shares as
dividends or the conversion price is adjusted downward, we will file
prospectus supplements as necessary to update the number of shares of
common stock HFTP intends to sell, reflecting prior sales and changes
in the conversion price.
(2) Pursuant to the Securities Purchase Agreement, dated as of April 24,
1998, by and among us and the selling stockholder, we are required to at
all times have authorized, and reserved for the purpose of issuance, no
less than 150% of the number of shares of common stock issuable upon
conversion of the Series F Convertible Preferred Stock.
(3) HFTP Investment L.L.C. purchased all of the shares of Series F
Preferred Stock of both Brown Simpson Strategic Growth Fund Ltd. and
Brown Simpson Strategic Growth Fund L.P. pursuant to a purchase
agreement between the parties dated as of March 9, 1999. HFTP
Investment L.L.C. purchased all of the shares of Series F Preferred
Stock of both Themis Partners L.P. and Heracles Fund pursuant to a
purchase agreement between the parties dated as of October 21, 1999.
Promethean Investment Group L.L.C., a New York limited liability
company, or Promethean, is the investment advisor of HFTP Investment
LLC, or HFTP, and may be deemed to share beneficial ownership of the
shares beneficially owned by HFPT by reason of its voting control and
investment discretion over securities held by HFTP. Promethean
disclaims beneficial ownership of the shares beneficially owned by
HFTP. Promethean is indirectly controlled by Mr. James F. O'Brien.
Mr. O'Brien disclaims beneficial ownership of the shares beneficially
owned by Promethean and HFTP.
There has been no material relationship between the selling stockholder
and us in the past three years except as a result of ownership of the Series F
Convertible Preferred Stock.
PLAN OF DISTRIBUTION
The selling stockholder (or, subject to applicable law, its pledges,
donees, distributees, transferees or other successors in interest) may sell
shares from time to time in public transactions, on or off the Nasdaq National
Market, or private transactions, at prevailing market prices or at privately
negotiated prices, including but not limited to, one or any combination of the
following types of transactions:
- ordinary brokers' transactions;
- transactions involving cross or block trades or otherwise on the
Nasdaq National Market;
-13-
<PAGE>
- purchases by brokers, dealers or underwriters as principal and
resale by those purchasers for their own accounts pursuant to
this prospectus;
- "at the market," to or through market makers, or into an existing
market for our common stock;
- in other ways not involving market makers or established trading
markets, including the direct sales to purchasers or sales
effected through agents;
- through transactions in options, swaps or other derivatives
(whether exchange-listed or otherwise);
- in privately negotiated transactions; or
- to cover short sales.
In effecting sales, brokers or dealers engaged by the selling
stockholder may arrange for other brokers or dealers to participate in the
resales. The selling stockholder may enter into hedging transactions with
broker-dealers, and in connection with those transactions, broker-dealers may
engage in short sales of the shares. The selling stockholder also may sell
shares short and deliver the shares to close out such short positions. The
selling stockholder also may enter into option or other transactions with
broker-dealers that require the delivery to the broker-dealer of the shares,
which the broker-dealer may resell pursuant to this prospectus. The selling
stockholder also may pledge the shares to a financial institution, broker or
dealer. Upon a default, the financial institution, broker or dealer may
effect sales of the pledged shares pursuant to this prospectus. The selling
stockholder has advised us that it purchased the Series F Convertible
Preferred Stock in the ordinary course of its business and at the time the
selling stockholder purchased the Series F Convertible Preferred Stock it was
not a party to any agreement or other understanding to distribute the
securities, directly or indirectly.
Brokers, dealers or agents may receive compensation in the form of
commissions, discounts or concessions from selling the stockholder in amounts to
be negotiated in connection with the sale. The selling stockholder and any
participating brokers or dealers may be deemed to be "underwriters" within the
meaning of the Securities Act in connection with such sales. In such event, any
commission, discount or concession these "underwriters" receive may be deemed to
be underwriting compensation.
LEGAL MATTERS
The validity of the issuance of the shares offered in this prospectus
was passed upon for us by Pillsbury Madison & Sutro LLP, San Francisco,
California. A partner of Pillsbury Madison & Sutro LLP owns 15,000 shares of our
common stock and an option to acquire 20,000 shares of our common stock.
EXPERTS
The audited consolidated financial statements of the Company as of
December 31, 1997 and 1998 and for each of the three years in the period
ended December 31, 1998, incorporated by reference in this Registration
Statement, have been audited by Arthur Andersen LLP, independent public
accountants, as indicated in their report with respect thereto, and are
incorporated by reference herein in reliance upon the authority of said firm
as experts in giving said report.
-14-
<PAGE>
- -------------------------------------------------------------------------------
We have not authorized any dealer, salesperson or any other person to give
any information or to represent anything not contained in this prospectus. You
must not rely on any unauthorized information. This prospectus does not offer to
sell or seek an offer to buy any shares in any jurisdiction where it is
unlawful. The information contained in this prospectus is correct only as of the
date of this prospectus, regardless of the time of the delivery of this
prospectus or any sale of the shares.
----------------------------
TABLE OF CONTENTS
<TABLE>
<CAPTION>
PAGE
----
<S> <C>
Risk Factors.........................................................2
Additional or Updated Risk Factors..................................10
Special Note Regarding Forward-Looking Information..................10
Where You Can Find More Information.................................10
Use of Proceeds.....................................................11
Issuance of Common Stock to the Selling
Stockholders........................................................11
Income Tax Considerations...........................................12
Selling Stockholder.................................................13
Plan of Distribution................................................13
Legal Matters.......................................................14
Experts.............................................................14
</TABLE>
- -------------------------------------------------------------------------------
3,900,000 Shares
Common Stock
THE IMMUNE
RESPONSE CORPORATION
----------------------------
PROSPECTUS
----------------------------
_______________, 2000
- -------------------------------------------------------------------------------
<PAGE>
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION
The following table sets forth the various expenses in connection with
the sale and distribution of the securities being registered hereby, other than
underwriting discounts and commissions. All amounts are estimated except the
Securities and Exchange Commission registration fee and the Nasdaq National
Market listing fee.
<TABLE>
<CAPTION>
Amount
-------------------
<S> <C>
SEC registration fee $2,255.30
Accounting fees and expenses 10,000.00
Legal fees and expenses 15,000.00
Registrar and transfer agent's fees 2,500.00
NNM listing fee 17,500.00
Miscellaneous fees and expenses 2,744.70
--------
Total $50,000.00
</TABLE>
ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS
Section 145 of the Delaware General Corporation Law (the "Delaware
GCL") permits our board of directors to indemnify any person against expenses
(including attorneys' fees), judgments, fines and amounts paid in settlement
actually and reasonably incurred by him in connection with any threatened,
pending or completed action, suit or proceeding in which such person is made a
party by reason of his being or having been a director, officer, employee or
agent of ours, in terms sufficiently broad to permit such indemnification under
certain circumstances for liabilities (including reimbursement for expenses
incurred) arising under the Securities Act of 1933, as amended (the "Act"). The
Delaware GCL provides that indemnification pursuant to its provisions is not
exclusive of other rights of indemnification to which a person may be entitled
under any by-law, agreement, vote of stockholders or disinterested directors, or
otherwise.
Article VII of our Restated Certificate of Incorporation, as amended,
and Article V of our Bylaws, provide for indemnification of our directors,
officers, employees and other agents to the maximum extent permitted by law.
In addition, we have entered into separate indemnification agreements
with our directors and officers that will require us, among other things, to
indemnify them against certain liabilities that may arise by reason of their
status or service as directors or officers to the fullest extent not prohibited
by law.
II-1
<PAGE>
ITEM 16. EXHIBITS
<TABLE>
<CAPTION>
Exhibit
Number Description of Document*
---------- ---------------------------------------------------------
<S> <C>
3(i)(1) Our Restated Certificate of Incorporation, as
amended by Certificate of Designations, Preferences and
Rights of Series F Convertible Preferred Stock.
5.1** Opinion of Pillsbury Madison & Sutro LLP regarding the
legality of the securities 5.1 being registered.
10.1(2) Securities Purchase Agreement dated as of April 24, 1998
by and among us and the selling stockholders.
10.2(2) Registration Rights Agreement dated as of April 24, 1998
by and among us and the selling stockholders.
23.1 Consent of independent public accountants.
23.2 Consent of Pillsbury Madison & Sutro LLP (included in its
opinion filed as Exhibit 5.1 to this Registration
Statement).
24.1* Power of Attorney.
</TABLE>
- ---------------
(1) Incorporated by reference to exhibit of the same number to our
report on Form 10-Q for the Quarter ended June 30, 1999.
(Commission File No. 0-18806).
(2) Incorporated by reference to the exhibits of the same number to our
report on Form 8-K dated April 24, 1998
** Previously filed.
ITEM 17. UNDERTAKINGS
Insofar as indemnification for liabilities arising under the Securities
Act of 1933, as amended (the "Act"), may be permitted to our directors, officers
and controlling persons pursuant to the foregoing provisions, or otherwise, we
have been advised that in the opinion of the Securities and Exchange Commission
such indemnification is against public policy as expressed in the Act and is,
therefore, unenforceable. In the event that a claim for indemnification against
such liabilities (other than the payment by us of expenses incurred or paid by a
director, officer or controlling person of ours in the successful defense of any
action, suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, we will, unless in
the opinion of our counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question whether such
indemnification by us is against public policy as expressed in the Act and will
be governed by the final adjudication of such issue.
We hereby undertake:
(1) To file during any period in which offers or sales are
being made, a post-effective amendment to this registration statement;
(i) to include any prospectus required
II-2
<PAGE>
by Section 10(a)(3) of the Act; (ii) to reflect in the prospectus any
facts or events arising after the effective date of the registration
statement (or the most recent post-effective amendment thereof) which,
individually or in the aggregate, represent a fundamental change in the
information set forth in this registration statement; and (iii) to
include any material information with respect to the plan of
distribution not previously disclosed in this registration statement or
any material change to such information in this registration statement;
provided, however, that paragraphs (i) and (ii) do not apply if the
information required to be included in a post-effective amendment by
those paragraphs is contained in periodic reports filed by us pursuant
to Section 13 or Section 15(d) of the Securities Exchange Act of 1934,
as amended (the "Exchange Act") that are incorporated by reference in
this registration statement.
(2) That, for the purpose of determining any liability under
the Act, each post-effective amendment that contains a form of
prospectus shall be deemed to be a new registration statement relating
to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering
thereof.
(3) To remove from registration by means of a post-effective
amendment any of the securities being registered which remain unsold at
the termination of the offering.
(4) For purposes of determining any liability under the Act,
each filing of our annual report pursuant to Section 13(a) or Section
15(d) of the Exchange Act which is incorporated by reference in this
registration statement shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering
of such securities at that time shall be deemed to be the initial bona
fide offering thereof.
II-3
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, we
certify that we have reasonable grounds to believe that we meet all of the
requirements for filing on Form S-3, and have duly caused this second
amendment to registration statement to be signed on our behalf by the
undersigned, thereunto duly authorized, in the City of Carlsbad, State of
California, March 16, 2000.
THE IMMUNE RESPONSE CORPORATION
By /s/ Dennis J. Carlo, Ph.D.
----------------------------------------
Dennis J. Carlo, Ph.D.
President and Chief Executive Officer
Pursuant to the requirements of the Securities Act of 1933, this
second amendment to registration statement has been signed by the following
persons in the capacities and on the dates indicated:
<TABLE>
<CAPTION>
Signature Title Date
--------- ----- ----
<S> <C> <C>
/s/ Dennis J. Carlo, Ph.D. President, Chief Executive Officer, March 16, 2000
- -------------------------------------- Chief Scientific Officer and
Dennis J. Carlo, Ph.D. Director (Principal Executive Officer)
II-4
<PAGE>
/s/ Howard Sampson Vice President Finance, Chief March 16, 2000
- -------------------------------------- Financial Officer and Treasurer
Howard Sampson (Principal Financial and Principal
Accounting Officer)
Chairman of the Board of
* Directors March 16, 2000
- --------------------------------------
James B. Glavin
* Director March 16, 2000
- --------------------------------------
Kevin B. Kimberlin
* Director March 16, 2000
- --------------------------------------
Melvin Perelman
* Director March 16, 2000
- --------------------------------------
William M. Sullivan
Director March 16, 2000
- --------------------------------------
Philip M. Young
* By: /s/ Howard Sampson
- --------------------------------------
Howard Sampson
(attorney-in-Fact)
</TABLE>
II-5
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit
Number Description of Document
- ------ -----------------------------------------------------------------
<S> <C>
3(i)(1) Our Restated Certificate of Incorporation, as
amended by Certificate of Designations, Preferences and
Rights of Series F Convertible Preferred Stock
5.1* Opinion of Pillsbury Madison & Sutro LLP regarding the legality
of the securities being 5.1 registered.
10.1(2) Securities Purchase Agreement dated as of April 24, 1998 by
and among us and the selling stockholder.
10.2(2) Registration Right Agreement dated as of April 24, 1998 by and
among us and the selling stockholder.
23.1 Consent of independent public accountants.
23.2 Consent of Pillsbury Madison & Sutro LLP (included in its opinion
filed as Exhibit 5.1 to this Registration Statement).
24.1* Power of Attorney.
* Previously filed.
(1) Incorporated by reference to exhibit of the same nuber to our report on
Form 10-Q for the Quarter end June 30, 1999. (Commission File No.
0-18806).
(2) Incorporated by reference to the exhibit of the same number to our
report our Form 8-K dated April 24, 1998
</TABLE>
<PAGE>
EXHIBIT 23.1
CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS
As independent public accountants, we hereby consent to the
incorporation by reference in this registration statement of our report dated
January 21, 1999 included in The Immune Response Corporation's Form 10-K for
the year ended December 31, 1998 and to all references to our Firm included
in this registration statement.
San Diego, California
March 16, 2000
/s/ ARTHUR ANDERSEN LLP
